A5103082527- Cervical Cancer and HPV Research
- Genital Health and Disease
- Global Cancer Incidence and Screening
- Hepatitis B Virus Studies
- Endometrial and Cervical Cancer Treatments
- Reproductive tract infections research
- Molecular Biology Techniques and Applications
- Colorectal Cancer Screening and Detection
- Colorectal and Anal Carcinomas
- Viral-associated cancers and disorders
- AI in cancer detection
- Head and Neck Cancer Studies
- Cancer Genomics and Diagnostics
- Epigenetics and DNA Methylation
- Ovarian cancer diagnosis and treatment
- Cancer-related molecular mechanisms research
- Viral Infections and Outbreaks Research
- T-cell and Retrovirus Studies
- Immunotherapy and Immune Responses
- Virus-based gene therapy research
- Reproductive System and Pregnancy
- Urological Disorders and Treatments
- Women's cancer prevention and management
- Respiratory viral infections research
- Animal Genetics and Reproduction
National Cancer Institute
2016-2025
Division of Cancer Epidemiology and Genetics
2011-2024
National Institutes of Health
2012-2024
Rwanda Development Board
2024
Albert Einstein College of Medicine
2013-2023
Cancer Institute (WIA)
2002-2021
United States Department of Health and Human Services
2005-2021
Colorado Permanente Medical Group
2021
Yeshiva University
2010-2020
Emory University
2016-2020
An update to the American Cancer Society (ACS) guideline regarding screening for early detection of cervical precancerous lesions and cancer is presented. The guidelines are based on a systematic evidence review, contributions from 6 working groups, recent symposium cosponsored by ACS, Colposcopy Cervical Pathology, Clinical which was attended 25 organizations. new recommendations address age-appropriate strategies, including use cytology high-risk human papillomavirus (HPV) testing,...
Human papillomavirus (HPV) types 16 and 18 cause 60%-70% of cervical cancer worldwide, other HPV virtually all remaining cases. Pooled testing for 13 oncogenic types, including HPV16 18, is currently used in clinical practice triage equivocal cytology and, conjunction with Pap tests, an option general screening among women 30 years age older. It not clear to what extent individual identification or HPV18 as adjunct pooled might effectively identify at particularly high risk its immediate...
Table: of ContentsA. EXECUTIVE SUMMARY Updated US consensus guidelines for management cervical screening abnormalities are needed to accommodate the 3 available strategies: primary human papillomavirus (HPV) screening, cotesting with HPV testing and cytology, cytology alone. New data indicate that a patient's risk developing precancer or cancer can be estimated using current test results previous biopsy results, while considering personal factors such as age immunosuppression. Routine...
The terminology for human papillomavirus(HPV)–associated squamous lesions of the lower anogenital tract has a long history marked by disparate diagnostic terms derived from multiple specialties. It often does not reflect current knowledge HPV biology and pathogenesis. A consensus process was convened to recommend unified across sites. goal create histopathologic nomenclature system that reflects biology, optimally uses available biomarkers, facilitates clear communication different medical...
An update to the American Cancer Society (ACS) guideline regarding screening for early detection of cervical precancerous lesions and cancer is presented. The guidelines are based on a systematic evidence review, contributions from 6 working groups, recent symposium cosponsored by ACS, Colposcopy Cervical Pathology, Clinical which was attended 25 organizations. new recommendations address age-appropriate strategies, including use cytology high-risk human papillomavirus (HPV) testing,...
Given the strong etiologic link between high-risk HPV infection and cervical cancer testing is now being considered as an alternative for cytology-based screening. Many test systems have been developed that can detect broad spectrum of hrHPV types in one assay. However, screening purposes detection not inherently useful unless it informative presence high-grade intraepithelial neoplasia (CIN 2/3) or cancer. Candidate tests to be used should reach optimal balance clinical sensitivity...
Health professionals and the public need to understand natural history of human papillomavirus (HPV) infections cervix best use information provided by new molecular screening tests. We investigated outcomes 800 carcinogenic HPV detected in 599 women at enrollment into a population-based cohort (Guanacaste, Costa Rica). For individual infections, we calculated cumulative proportions three (viral clearance, persistence without cervical intraepithelial neoplasia grade 2 or worse [CIN2+], with...
Cervical cancer is caused by persistent infection with human papillomavirus (HPV). Most infections and associated lesions clear spontaneously. It important to define the determinants timing of clearance, so that viral persistence can be recognized managed.We investigated HPV natural history among 4504 subjects from ALTS (Atypical Squamous Cells Undetermined Significance/Low-Grade Intraepithelial Lesions Triage Study). A discrete-time Markov model was used simultaneously describe prevalence,...
Cross-sectional human papillomavirus (HPV) DNA prevalence peaks at young ages, reflecting sexual acquisition and typically rapid clearance. In some populations, HPV demonstrates a second peak in older women. Longitudinal data may help to explain this peak.We followed population-based cohort of 7237 women Guanacaste, Costa Rica, which we had previously observed the baseline We tested for >40 types by polymerase chain reaction. analyzed age-specific patterns persistence 5-7 years after...
BackgroundDetailed epidemiologic studies of cervical type-specific human papillomavirus (HPV) infection in large populations are scarce MethodsWe recruited a population-based cohort Guanacaste, Costa Rica. Participants were interviewed, screened for neoplasia, and tested >40 HPV types by use MY09/11 L1 consensus primer polymerase chain reaction. We estimated the risk factors associations between infections intraepithelial neoplasia (CIN) cancer 8514 sexually active women who had not...
In Brief OBJECTIVE: To estimate the fraction of cervical intraepithelial neoplasia 2 (CIN 2) that might regress if untreated using data from Atypical Squamous Cells Undetermined Significance/Low-Grade Intraepithelial Lesions Triage Study (ALTS). METHODS: We compared cumulative occurrence CIN (n=397) and 3 or more severe (n=542) diagnosed by Pathology Quality Control Group in three trial arms—immediate colposcopy, human papillomavirus (HPV) triage, conservative management—over 2-year duration...
Histopathologic diagnosis of cervical biopsies determines clinical management patients with an abnormal cancer-screening test yet is prone to poor interobserver reproducibility. Immunohistochemical staining for biomarkers related the different stages carcinogenesis may provide objective standards reduce diagnostic variability biopsy evaluations but systematic, rigorous their potential utility are lacking. To address human papillomavirus (HPV) L1, p16(INK4a), and Ki-67 immunohistochemical...